Physician profile
Charles Harper
NPI 1063620961
$13,141.97
in general payments reported to CMS, 2019-2025
65 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,809 · 2021: $2,388 · 2022: $1,681 · 2023: $3,225 · 2024: $1,262 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,352 · Travel and Lodging: $1,395 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.39 |
| Travel and Lodging | $1,394.82 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,719.82 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,265.65 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $1,070.24 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $952.55 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $907.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $872.79 | 2019-2025 | |
| Amgen INC. | $707.43 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $618.45 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $515.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $406.89 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $353.07 | 2019-2025 | |
| Amarin Pharma, INC. | $282.40 | 2020-2021 | |
| Glaxosmithkline, LLC. | $278.99 | 2019-2023 | Nucala, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $275.54 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Mannkind Corporation | $255.73 | 2020-2021 |
Show all 53 companies
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.